UNSPSC 51332833: Acepromazine maleate

This classification denotes a dopamine antagonist with the molecular formula C19H22N2OS.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37862HP2OM, chemically known as 2-acetyl-10-(3-(dimethylamino)propyl)phenothiazine, maleate but more generally known as acepromazine maleate, which bears US NIH Compound Identifier 5476753. The base compound, Acepromazine, also comes in base form. European Medicines Agency schedules Acepromazine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21524.

UNSPSC 51332833 Acepromazine maleate is a Commodity code representing pharmaceutical products, but the recent state and local solicitations tagged under this code do not reflect acepromazine procurement. Instead, the opportunities posted under this code cover naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs — indicating a mismatch between the code's nominal scope and the work actually being solicited. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances, suggesting that when pharmaceutical procurement does occur under related codes, it spans public health, employee benefit programs, and institutional supply chains across county and state infrastructure.

Relevant recent opportunities show activity in Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB in June 2026 (due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the county community health building. The Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP in January 2026 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with contract awards effective July 1, 2026 and administered through three authorized wholesalers. The code itself shows little relevant recent activity aligned with acepromazine procurement specifically.